11/24/2014 - 11:03am

Omnicare and McKesson on Monday announced the signing of an expanded agreement to include the sourcing and distribution of branded, specialty and generic pharmaceuticals. 

11/20/2014 - 10:51am

Decision Resources Group found that sales of biosimilar versions of the granulocyte colony-stimulating factors (G-CSFs) filgrastim and pegfilgrastim could reach $1.8 billion in the United States by 2023. 

11/20/2014 - 10:13am

More specialty drug innovation, greater patient access to medicines and reduced impact from patent expiries will be the primary drivers of an increase in global medicine spending of up to 30% by 2018.

11/17/2014 - 12:26pm

Pharmaceutical sales through HDMA-member traditional primary distributors reached nearly $305 billion in 2013.

11/17/2014 - 10:54am

Genzyme, a Sanofi company, on Friday announced that the Food and Drug Administration approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis. 

11/14/2014 - 10:34am

Walgreens earlier this week opened its first Walgreens Specialty Pharmacy in the Omaha, Neb. market.

 

11/11/2014 - 9:35am

UCB, Advent International and Avista Capital Partners last week announced they have entered into a definitive agreement providing for the acquisition of UCB’s U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals, by Advent and Avista.

11/06/2014 - 3:46pm

Diplomat Pharmacy on Wednesday announced the addition of Martino Luu to their senior leadership team as VP innovation and process improvement.

 

11/03/2014 - 12:41pm

The RAND Corp. projected that the introduction of biosimilar drugs in the United States will reduce direct spending on biologics by $44.2 billion from 2014 to 2024.